Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Proteomes 2013, 1(2), 159-179; doi:10.3390/proteomes1020159
Review

High-Throughput Proteomic Approaches to the Elucidation of Potential Biomarkers of Chronic Allograft Injury (CAI)

,
,
,
,
 and *
Received: 19 July 2013; in revised form: 6 September 2013 / Accepted: 9 September 2013 / Published: 23 September 2013
(This article belongs to the Special Issue Insights and Trends into Proteome Science)
View Full-Text   |   Download PDF [944 KB, updated 25 September 2013; original version uploaded 23 September 2013]
Abstract: This review focuses on the role of OMICs technologies, concentrating in particular on proteomics, in biomarker discovery in chronic allograft injury (CAI). CAI is the second most prevalent cause of allograft dysfunction and loss in the first decade post-transplantation, after death with functioning graft (DWFG). The term CAI, sometimes referred to as chronic allograft nephropathy (CAN), describes the deterioration of renal allograft function and structure as a result of immunological processes (chronic antibody-mediated rejection), and other non-immunological factors such as calcineurin inhibitor (CNI) induced nephrotoxicity, hypertension and infection. Current methods for assessing allograft function are costly, insensitive and invasive; traditional kidney function measurements such as serum creatinine and glomerular filtration rate (GFR) display poor predictive abilities, while the current “gold-standard” involving histological diagnosis with a renal biopsy presents its own inherent risks to the overall health of the allograft. As early as two years post-transplantation, protocol biopsies have shown more than 50% of allograft recipients have mild CAN; ten years post-transplantation more than 50% of the allograft recipients have progressed to severe CAN which is associated with diminishing graft function. Thus, there is a growing medical requirement for minimally invasive biomarkers capable of identifying the early stages of the disease which would allow for timely intervention. Proteomics involves the study of the expression, localization, function and interaction of the proteome. Proteomic technologies may be powerful tools used to identify novel biomarkers which would predict CAI in susceptible individuals. In this paper we will review the use of proteomics in the elucidation of novel predictive biomarkers of CAI in clinical, animal and in vitro studies.
Keywords: chronic allograft injury; chronic allograft nephropathy; IF/TA; calcineurin inhibitors; cyclosporine; transplantation; proteomics; biomarkers chronic allograft injury; chronic allograft nephropathy; IF/TA; calcineurin inhibitors; cyclosporine; transplantation; proteomics; biomarkers
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Cassidy, H.; Slyne, J.; Frain, H.; Slattery, C.; Ryan, M.P.; McMorrow, T. High-Throughput Proteomic Approaches to the Elucidation of Potential Biomarkers of Chronic Allograft Injury (CAI). Proteomes 2013, 1, 159-179.

AMA Style

Cassidy H, Slyne J, Frain H, Slattery C, Ryan MP, McMorrow T. High-Throughput Proteomic Approaches to the Elucidation of Potential Biomarkers of Chronic Allograft Injury (CAI). Proteomes. 2013; 1(2):159-179.

Chicago/Turabian Style

Cassidy, Hilary; Slyne, Jennifer; Frain, Helena; Slattery, Craig; Ryan, Michael P.; McMorrow, Tara. 2013. "High-Throughput Proteomic Approaches to the Elucidation of Potential Biomarkers of Chronic Allograft Injury (CAI)." Proteomes 1, no. 2: 159-179.

Proteomes EISSN 2227-7382 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert